Music intervention for children with myotonic dystrophy type 1
Music Intervention for Brain-Heart Disease in Myotonic Dystrophy Type 1 (DM1)
This study is testing if weekly music sessions can help children with myotonic dystrophy type 1 feel better and improve their physical and mental skills.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 13 (estimated) |
| Ages | 6 Years to 18 Years |
| Sex | All |
| Sponsor | Children's Hospital of Eastern Ontario Academic / other |
| Locations | 1 site (Ottawa, Ontario) |
| Trial ID | NCT06809049 on ClinicalTrials.gov |
What this trial studies
This interventional study aims to assess the feasibility and tolerability of Dalcroze music education for children aged 6 to 18 with congenital myotonic dystrophy type 1 (DM1). Participants will engage in weekly music sessions over a period of 10 weeks, with their physical and cognitive assessments compared to baseline measurements. The study will also collect biological samples and utilize wearable devices to identify potential brain-heart biomarkers and outcome measures for future research. Qualitative feedback from participants will help evaluate the intervention's acceptability within this population.
Who should consider this trial
Good fit: Ideal candidates are children aged 6 to 18 with genetically confirmed congenital or infantile-onset myotonic dystrophy type 1.
Not a fit: Patients who are non-verbal or have insufficient English language skills may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could improve brain and heart symptoms in children with myotonic dystrophy type 1.
How similar studies have performed: While this approach is innovative, similar music interventions have shown promise in other populations, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants between the ages of 6 to 18 with genetically confirmed congenital or infantile-onset myotonic dystrophy type 1 (DM1). * Participants willing to stay on stable medication from the day of screening to end of study. Exclusion Criteria: * Insufficient English language skills to complete required assessments and questionnaires. * Participant is non-verbal. * Failure to provide signed informed consent by participant or designated decision maker (i.e. parent, legal guardian or power of attorney). * Failure to provide signed informed consent by parents/caregivers for dyad participation. * Participant is not a resident of Canada, due to risk of attrition. * Patients for whom - in the opinion of the investigator - it would not be safe to participate in the study.
Where this trial is running
Ottawa, Ontario
- Children's Hospital of Eastern Ontario — Ottawa, Ontario, Canada (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.